AU2001257006A1 - Substituted lactams as inhibitors of abeta protein production - Google Patents
Substituted lactams as inhibitors of abeta protein productionInfo
- Publication number
- AU2001257006A1 AU2001257006A1 AU2001257006A AU5700601A AU2001257006A1 AU 2001257006 A1 AU2001257006 A1 AU 2001257006A1 AU 2001257006 A AU2001257006 A AU 2001257006A AU 5700601 A AU5700601 A AU 5700601A AU 2001257006 A1 AU2001257006 A1 AU 2001257006A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibitors
- protein production
- substituted lactams
- abeta protein
- abeta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19654900P | 2000-04-11 | 2000-04-11 | |
US50196549 | 2000-04-11 | ||
PCT/US2001/011714 WO2001077086A1 (en) | 2000-04-11 | 2001-04-11 | SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001257006A1 true AU2001257006A1 (en) | 2001-10-23 |
Family
ID=22725848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001257006A Abandoned AU2001257006A1 (en) | 2000-04-11 | 2001-04-11 | Substituted lactams as inhibitors of abeta protein production |
Country Status (6)
Country | Link |
---|---|
US (7) | US6632812B2 (en) |
EP (1) | EP1289966A1 (en) |
JP (1) | JP2004500419A (en) |
AU (1) | AU2001257006A1 (en) |
CA (1) | CA2404273A1 (en) |
WO (1) | WO2001077086A1 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632812B2 (en) * | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
US20100009966A1 (en) * | 2001-04-11 | 2010-01-14 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of abeta protein production |
US7146209B2 (en) * | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
AU2001261728A1 (en) | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
WO2003057165A2 (en) | 2002-01-04 | 2003-07-17 | The Rockefeller University | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
US7684859B2 (en) * | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
JP2006500318A (en) * | 2002-04-25 | 2006-01-05 | ブレインスゲート リミテッド | Method and apparatus for adjusting the characteristics of BBB and cerebral circulation using nerve excitatory and / or neurosuppressive effects of odorants on the intracranial nerve |
US7001901B2 (en) | 2002-08-27 | 2006-02-21 | Bristol-Myers Squibb Company | Tetrazolylpropionamides as inhibitors of Aβ protein production |
JP2006515999A (en) * | 2002-11-14 | 2006-06-15 | ブレインズゲート リミティド | Surgical tools and techniques for stimulation |
CA2514267C (en) | 2003-02-04 | 2011-05-17 | F. Hoffmann-La Roche Ag | Malonamide derivatives as gamma-secretase inhibitors |
US7475413B2 (en) * | 2003-07-31 | 2009-01-06 | Inphase Technologies, Inc. | Data storage cartridge having a reduced thickness segment |
SI1711470T1 (en) * | 2003-09-09 | 2009-08-31 | Hoffmann La Roche | Malonamide derivatives blocking the activtiy of gamma-secretase |
CN1894217B (en) | 2003-10-06 | 2011-09-21 | 弗·哈夫曼-拉罗切有限公司 | Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
WO2006021957A2 (en) * | 2004-08-23 | 2006-03-02 | Brainsgate Ltd. | Concurrent bilateral spg modulation |
RU2440342C2 (en) * | 2006-03-27 | 2012-01-20 | Ф.Хоффманн-Ля Рош Аг | MALONAMIDE DERIVATIVES AS γ-SECRETASE INHIBITORS |
US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
MX2009007864A (en) | 2007-02-02 | 2009-07-31 | Hoffmann La Roche | 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives. |
WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
MX2009011923A (en) * | 2007-05-10 | 2009-11-18 | Amr Technology Inc | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin. |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
PT2222636E (en) | 2007-12-21 | 2013-07-16 | Ligand Pharm Inc | Selective androgen receptor modulators (sarms) and uses thereof |
US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
CA2941035A1 (en) | 2008-07-28 | 2010-02-04 | Blanchette Rockefeller Neurosciences Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
US9023767B2 (en) * | 2009-05-07 | 2015-05-05 | Memorial Sloan-Kettering Cancer Center | γ-Secretase substrates and methods of use |
WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
WO2012033831A2 (en) | 2010-09-07 | 2012-03-15 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for gamma-secretase assay |
TWI530489B (en) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
TWI614238B (en) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof |
US9133126B2 (en) | 2012-09-21 | 2015-09-15 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzoazepinone compounds |
JP2015531792A (en) | 2012-09-21 | 2015-11-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
CN105308030A (en) | 2012-09-21 | 2016-02-03 | 百时美施贵宝公司 | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
EP2897954B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
WO2014047390A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
WO2014047397A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
JP2015533811A (en) | 2012-09-21 | 2015-11-26 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | N-substituted bis (fluoroalkyl) 1,4-benzodiazepinone compounds |
US9187434B2 (en) | 2012-09-21 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinones compounds |
US9492469B2 (en) | 2013-04-04 | 2016-11-15 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
EP2878335B1 (en) | 2013-11-10 | 2018-01-03 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
CN111592459B (en) * | 2020-06-28 | 2021-10-15 | 北京博萃循环科技有限公司 | Carboxylic acid compound, preparation method and application thereof |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2934355A1 (en) | 1979-08-24 | 1981-03-12 | Bayer Ag, 5090 Leverkusen | Antibacterial alpha-amino-lactam urethane and thio:urethane derivs. - prepd. e.g. by reaction of an alpha-amino-lactam with a carbonic or thiocarbonic acid ester halide |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
DK0411668T4 (en) | 1989-08-04 | 1999-08-09 | Merck Sharp & Dohme | Central cholecystokinin antagonists for the treatment of mental disorders |
CA2026856A1 (en) | 1989-10-05 | 1991-04-06 | Mark G. Bock | 3-substituted-1,4-benzodiazepines useful as oxytocin |
IE904560A1 (en) | 1989-12-18 | 1991-06-19 | Merck & Co Inc | New benzodiazepine analogs |
US5576829A (en) * | 1990-10-08 | 1996-11-19 | Nikon Corporation | Method and apparatus for inspecting a phase-shifted mask |
US5206235A (en) * | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
US5389631A (en) | 1991-10-29 | 1995-02-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
AU671477B2 (en) | 1992-07-29 | 1996-08-29 | Merck Sharp & Dohme Limited | Benzodiazepine derivatives |
US5283241A (en) | 1992-08-28 | 1994-02-01 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5872596A (en) * | 1992-09-28 | 1999-02-16 | Canon Kabushiki Kaisha | Device for widening the dynamic range of solid-state image pickup elements |
US5389831A (en) * | 1992-12-17 | 1995-02-14 | Vlsi Technology, Inc. | Clock generator for providing a pair of nonoverlapping clock signals with adjustable skew |
SG63579A1 (en) | 1992-12-21 | 1999-03-30 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
MX9308016A (en) | 1992-12-22 | 1994-08-31 | Lilly Co Eli | HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITING COMPOUNDS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM. |
CA2160786A1 (en) | 1993-05-14 | 1994-11-24 | James C. Marsters, Jr. | Ras farnesyl transferase inhibitors |
WO1994029273A1 (en) | 1993-06-09 | 1994-12-22 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
NZ264143A (en) | 1993-08-09 | 1996-11-26 | Lilly Co Eli | Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production |
US5691339A (en) * | 1993-08-25 | 1997-11-25 | The Green Cross Corporation | Circulatory disorder improving agent |
US5545735A (en) | 1993-10-04 | 1996-08-13 | Merck & Co., Inc. | Benzo-Fused Lactams promote release of growth hormone |
US5426185A (en) | 1993-11-22 | 1995-06-20 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
WO1996005827A1 (en) * | 1994-08-18 | 1996-02-29 | Merck & Co., Inc. | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines |
FR2716509B1 (en) * | 1994-01-19 | 1996-04-12 | Alliedsignal Automotive Espana | Disc brake with increased safety. |
US5514716A (en) | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
CA2196062A1 (en) | 1994-07-29 | 1996-02-15 | Yoshinari Sato | Benzodiazepine derivatives |
US5550128A (en) * | 1994-09-09 | 1996-08-27 | Nair; Madhavan G. | Enantiomers of gamma methylene 10-deaza aminopterin and process for preparing the same |
US5661161A (en) | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1996017833A1 (en) | 1994-12-09 | 1996-06-13 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
US5639746A (en) | 1994-12-29 | 1997-06-17 | The Procter & Gamble Company | Hydroxamic acid-containing inhibitors of matrix metalloproteases |
EP0799189A4 (en) | 1994-12-13 | 1999-03-17 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
DE19500040A1 (en) | 1995-01-03 | 1996-07-04 | Basf Ag | Process for the preparation of aliphatic alpha, omega-aminonitriles in the gas phase |
WO1996024608A1 (en) * | 1995-02-07 | 1996-08-15 | Biosearch Italia S.P.A. | Basic oxazoline-amide derivatives of ge 2270 and ge 2270-like antibiotics |
US5672598A (en) | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5578629A (en) | 1995-03-29 | 1996-11-26 | Merck & Co., Inc. | Benzamide-containing inhibitors of farnesyl-protein transferase |
GB9507799D0 (en) | 1995-04-18 | 1995-05-31 | British Biotech Pharm | Metalloproteinase inhibitors |
US5673437A (en) * | 1995-05-08 | 1997-10-07 | Chase Ergonomics Inc. | Vibration attenuating member and method of making same |
US5710171A (en) | 1995-05-24 | 1998-01-20 | Merck & Co., Inc. | Bisphenyl inhibitors of farnesyl-protein transferase |
EP0828754B1 (en) | 1995-05-29 | 2005-02-02 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5691331A (en) * | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides |
US5726171A (en) * | 1995-06-07 | 1998-03-10 | Merck & Co Inc | N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo B! 1,4!diazepin-3yl)-acetamides |
EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
CZ292617B6 (en) | 1995-11-23 | 2003-11-12 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors and pharmaceutical preparation containing thereof |
JP2000504014A (en) | 1996-01-30 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | Farnesyl-protein transferase inhibitor |
US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000507585A (en) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | Inhibitors of farnesyl protein transferase |
AU707416B2 (en) | 1996-04-03 | 1999-07-08 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5891889A (en) | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5885995A (en) | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036879A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5965578A (en) | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0952842A2 (en) | 1996-04-18 | 1999-11-03 | Merck & Co., Inc. | A method of treating cancer |
EP0934270A1 (en) | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
US5703129A (en) | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
WO1998016523A2 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
PL323130A1 (en) | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
HUP0000492A3 (en) | 1996-11-22 | 2000-06-28 | Lilly Co Eli | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
EP0942923A2 (en) | 1996-11-22 | 1999-09-22 | Elan Pharmaceuticals, Inc. | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
JP2001504498A (en) | 1996-11-22 | 2001-04-03 | エラン・ファーマシューティカルズ・インコーポレイテッド | N- (aryl / heteroaryl / alkylacetyl) amino acid amides and pharmaceutical compositions thereof, and methods of inhibiting the release of β-amyloid peptide and / or the synthesis thereof using the compounds |
EP0944580A2 (en) | 1996-11-22 | 1999-09-29 | Elan Pharmaceuticals, Inc. | N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide release and/or its synthesis |
TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
IL129820A0 (en) | 1996-12-23 | 2000-02-29 | Elan Pharm Inc | Cycloalkyl lactam lactone and related compounds as beta-amyloid peptide release inhibitors |
WO1998028980A1 (en) | 1996-12-30 | 1998-07-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2002241368A (en) * | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | New benzolactam derivative and pharmaceutical composition containing the same |
WO1998037079A1 (en) | 1997-02-19 | 1998-08-27 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as nos inhibitors |
US5817658A (en) * | 1997-03-14 | 1998-10-06 | Merck & Company, Inc. | Method for treating Meniere's disease |
WO1998041510A1 (en) | 1997-03-14 | 1998-09-24 | Shionogi & Co., Ltd. | Novel benzolactam derivatives and medicinal compositions comprising the same |
JP2001524079A (en) | 1997-04-07 | 2001-11-27 | メルク エンド カンパニー インコーポレーテッド | How to treat cancer |
US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
DE19726427A1 (en) | 1997-06-23 | 1998-12-24 | Boehringer Mannheim Gmbh | Pyrimidine-2,4,6-trione derivatives, processes for their preparation and medicaments containing these compounds |
GB9715030D0 (en) | 1997-07-18 | 1997-09-24 | British Biotech Pharm | Metalloproteinase inhibitors |
NZ502803A (en) | 1997-08-11 | 2001-11-30 | Cor Therapeutics Inc | Selective factor Xa inhibitors for treating diseases such as angina, myocardial infarction, transient ischemic attacks or diseases associated with undesired thrombosis |
NZ502876A (en) | 1997-08-11 | 2001-11-30 | Cor Therapeutics Inc | Fused bicyclic lactam selective factor Xa inhibitors for treating thrombosis related diseases |
EP1027042A4 (en) | 1997-09-29 | 2004-08-18 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
BR9812773A (en) * | 1997-12-22 | 2000-10-10 | Elan Pharm Inc | "polycyclic alpha-amino-epsilon-caprolactams and related compounds" |
EP1089981A1 (en) | 1998-06-22 | 2001-04-11 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis. |
US6552013B1 (en) * | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
JP2002518451A (en) | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ,インコーポレイテッド | Cyclic amino acid compound and pharmaceutical composition thereof, and method of inhibiting release of β-amyloid peptide and / or synthesis thereof using the compound |
JP2002518483A (en) | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ,インコーポレイテッド | Compounds for inhibiting β-amyloid peptide release and / or their synthesis |
WO1999067219A1 (en) | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
CA2347671A1 (en) | 1998-12-24 | 2000-07-06 | Dupont Pharmaceuticals Company | Succinoylamino benzodiazepines as inhibitors of a.beta. protein production |
IL147774A0 (en) * | 1999-09-13 | 2002-08-14 | Du Pont Pharm Co | Hydroxyalkanoyl aminolactams and related structures as inhibitors of as protein production |
US6632812B2 (en) * | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
US6709054B2 (en) * | 2002-01-22 | 2004-03-23 | Prescient Partners, L.P. | Slipcover wrapping technique |
-
2001
- 2001-04-11 US US09/832,455 patent/US6632812B2/en not_active Expired - Lifetime
- 2001-04-11 EP EP01930471A patent/EP1289966A1/en not_active Withdrawn
- 2001-04-11 WO PCT/US2001/011714 patent/WO2001077086A1/en not_active Application Discontinuation
- 2001-04-11 AU AU2001257006A patent/AU2001257006A1/en not_active Abandoned
- 2001-04-11 JP JP2001575561A patent/JP2004500419A/en active Pending
- 2001-04-11 CA CA002404273A patent/CA2404273A1/en not_active Abandoned
-
2003
- 2003-10-14 US US10/685,031 patent/US6900199B2/en not_active Expired - Lifetime
-
2004
- 2004-12-06 US US11/005,573 patent/US7276495B2/en not_active Expired - Lifetime
-
2006
- 2006-02-06 US US11/348,091 patent/US20060211679A1/en not_active Abandoned
-
2007
- 2007-01-19 US US11/655,637 patent/US7390802B2/en not_active Expired - Lifetime
- 2007-04-19 US US11/788,708 patent/US7498324B2/en not_active Expired - Fee Related
-
2009
- 2009-02-19 US US12/388,944 patent/US7655647B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6632812B2 (en) | 2003-10-14 |
US7390802B2 (en) | 2008-06-24 |
EP1289966A1 (en) | 2003-03-12 |
US20050234039A1 (en) | 2005-10-20 |
JP2004500419A (en) | 2004-01-08 |
US7655647B2 (en) | 2010-02-02 |
US20070173491A1 (en) | 2007-07-26 |
US20080221087A1 (en) | 2008-09-11 |
US7276495B2 (en) | 2007-10-02 |
US6900199B2 (en) | 2005-05-31 |
US20060211679A1 (en) | 2006-09-21 |
WO2001077086A1 (en) | 2001-10-18 |
US20040138201A1 (en) | 2004-07-15 |
CA2404273A1 (en) | 2001-10-18 |
US20090170831A1 (en) | 2009-07-02 |
US20020025955A1 (en) | 2002-02-28 |
US7498324B2 (en) | 2009-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001257006A1 (en) | Substituted lactams as inhibitors of abeta protein production | |
AU2001239791A1 (en) | Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production | |
AU7997600A (en) | Amino lactam sulfonamides as inhibitors of abeta protein production | |
IL151576A0 (en) | Cyclic lactams as inhibitors of a-beta protein production | |
AU2003265235A1 (en) | Non-affinity purification of proteins | |
IL147629A0 (en) | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | |
AU2002305205A1 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
GB0322515D0 (en) | Enzymes for specific fragmentation of proteins | |
AU2001280201A1 (en) | Methods of synthesizing cell-free protein | |
AU2002235189A1 (en) | Production of 6-aminocaproic acid | |
AU2002367147A1 (en) | Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | |
AU2001290075A1 (en) | Novel alkanoic acid derivatives | |
AU2002330453A1 (en) | Crystals of hydroxynorephedrine derivative | |
AU2001244692A1 (en) | Novel crystal form of pyrrolidylthiocarbapenem derivative | |
AU2002214286A1 (en) | Method of profiling protein | |
AU2002336746A1 (en) | Inhibitors of rnase p proteins as antibacterial compounds | |
AU2001292307A1 (en) | Non-deliquescent salt of 4-hydroxypiperidine derivative | |
AU2001249477A1 (en) | Lactams as inhibitors of a-beta protein production | |
AU2001265935A1 (en) | Production of biohydrolysates | |
AU2002210816A1 (en) | Process for preparation of beta-phenethylamine derivative | |
GB2384779B (en) | Method for the production of tagged proteins | |
AU2001284469A1 (en) | Methods for crystallization of hydroxycarboxylic acids | |
AU2002234066A1 (en) | Process for the production of amides | |
AU2002239568A1 (en) | Production of alkyl 6-aminocaproate | |
AU2002213477A1 (en) | Process for preparation of n-substituted 2-sulfanylimidazoles |